Stockholm – October 05, 2026 -- Moberg Pharma AB (OMX: MOB) reported that its topical onychomycosis treatment MOB-015 achieved mycological cure in 74.3% of evaluable Phase 3 patients regardless of baseline antifungal susceptibility, according to new peer-reviewed data published in the Journal of Fungi.

Taipei – October 05, 2026 -- AnnJi Pharmaceutical Co., Ltd. (TPEx: 7754) is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial for AJ201, an oral small molecule targeting spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, a rare inherited neuromuscular disorder with no FDA-approved treatment.

Tokyo – October 04, 2026 -- Celaid Therapeutics Inc. has completed the second close of its Series B financing round, raising JPY 400 million (approximately USD 2.6 million) with new backing from Shionogi & Co., Ltd. and Teikoku Ventures, Inc.

Melbourne – October 4, 2026 -- CSL and Alentis Therapeutics have signed an exclusive global collaboration to develop and commercialize lixudebart, a potential first-in-class therapy targeting claudin-1 for rare kidney and liver diseases, with CSL paying Alentis US$355 million upfront and up to US$1.2 billion in commercial milestones.

Hiroshima – October 3, 2026 -- Ractigen Therapeutics presented first-in-human data showing its systemically delivered small activating RNA (saRNA), RAG-18, produced 3.5- to 5.3-fold increases in sarcolemmal utrophin expression in boys with Duchenne muscular dystrophy (DMD), marking the first clinical proof-of-mechanism for RNA activation (RNAa) in a monogenic disease. The data were disclosed in a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026) in Hiroshima, Japan.

Shanghai/Hong Kong – – October 02, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) will present preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract Presentation at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2026), running November 4-8 at the Phoenix Convention Center in Arizona.

Cambridge/Shenzhen – October 02, 2026 -- XtalPi (HKEX: 2228) has moved its proprietary hair loss drug program into IND-enabling studies, with pharmacology, safety, and chemistry, manufacturing and controls (CMC) work underway to support a future Investigational New Drug application.

Cambridge, Mass. – – October 02, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) received a Nasdaq Staff Determination on October 1, 2026, confirming it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement by its September 29, 2026 deadline, triggering a potential delisting from The Nasdaq Capital Market.

Indianapolis – October 02, 2026 -- The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib), clearing the non-covalent BTK inhibitor as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion.

Houston – October 02, 2026 -- Researchers at Rice University, backed by the Rice Biotech Launch Pad, have developed an implantable device that produced therapeutic monoclonal antibodies continuously for one year across multiple preclinical models, with the platform now advancing toward human trials through biotech company Duracyte.